An Epidemiological Study of Cervical Cancer Trends Among Women with Human Immunodeficiency Virus

Overview

Journal Healthcare (Basel)

Specialty Health Services

Date 2024 Jun 26

PMID 38921292

Authors

Arlesia Mathis

Ukamaka D Smith

Vanessa Crowther

Torhonda Lee

Sandra Suther

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to examine cervical cancer among women with Human Immunodeficiency Virus (HIV) and to discuss targeted strategies to reduce the risk of developing cervical cancer. This study used retrospective data from surveillance reports collected between January 2001 and December 2012. Women with HIV/Acquired Immunodeficiency Syndrome (AIDS) were linked through a crosswalk file to Florida's cancer registry database to determine which women developed cervical cancer during this period. We examined the cervical cancer trends using age-adjusted cervical cancer rates to examine the changes over time; the geographic variations in cervical cancer and HIV across service areas using a Geographic Information System (GIS); and finally, the cervical cancer rates among women with HIV compared with the cervical cancer rates in the general population. The results show that, over time, the cervical cancer rates in women with HIV/AIDS decreased; however, we detected increases in the cervical cancer rates among women in the general population. The findings of this study show that more work is required to address cervical cancer. This growing burden of cervical cancer implies that targeted interventions are imperative to improving the health status of women with cervical cancer. If properly addressed, the potential to reduce and prevent cervical cancer is achievable.

References

Shiels M, Pfeiffer R, Gail M, Hall H, Li J, Chaturvedi A . Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103(9):753-62. PMC: 3086877. DOI: 10.1093/jnci/djr076. View

Bahena-Roman M, Sanchez-Aleman M, Contreras-Ochoa C, Lagunas-Martinez A, Olamendi-Portugal M, Lopez-Estrada G . Prevalence of active infection by herpes simplex virus type 2 in patients with high-risk human papillomavirus infection: A cross-sectional study. J Med Virol. 2020; 92(8):1246-1252. DOI: 10.1002/jmv.25668. View

Barnes A, Betts A, Borton E, Sanders J, Pruitt S, Werner C . Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS. 2018; 32(13):1861-1870. PMC: 6059987. DOI: 10.1097/QAD.0000000000001881. View

Li S, Wen X . Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999-2014). BMC Cancer. 2017; 17(1):726. PMC: 5678804. DOI: 10.1186/s12885-017-3734-2. View

Sausen D, Shechter O, Gallo E, Dahari H, Borenstein R . Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications. Cancers (Basel). 2023; 15(14). PMC: 10378257. DOI: 10.3390/cancers15143692. View

Grover S, Bhatia R, Friebel-Klingner T, Mathoma A, Vuylsteke P, Khan S . Cervical cancer screening in HIV-endemic countries: An urgent call for guideline change. Cancer Treat Res Commun. 2023; 34:100682. PMC: 9999385. DOI: 10.1016/j.ctarc.2023.100682. View

Zhou G, Koroukian S, Navale S, Schiltz N, Kim U, Rose J . Cancer burden in women with HIV on Medicaid: A nationwide analysis. Womens Health (Lond). 2023; 19:17455057231170061. PMC: 10192809. DOI: 10.1177/17455057231170061. View

Suk R, Hong Y, Rajan S, Xie Z, Zhu Y, Spencer J . Assessment of US Preventive Services Task Force Guideline-Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019. JAMA Netw Open. 2022; 5(1):e2143582. PMC: 8767443. DOI: 10.1001/jamanetworkopen.2021.43582. View

Nissim O, Dees A, Cooper S, Patel K, Lazenby G . Cervical Cancer Among Women With HIV in South Carolina During the Era of Effective Antiretroviral Therapy. J Low Genit Tract Dis. 2022; 26(2):109-114. DOI: 10.1097/LGT.0000000000000656. View

10.

Shiels M, Engels E . Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2016; 12(1):6-11. PMC: 5240042. DOI: 10.1097/COH.0000000000000327. View

11.

Cutrell J, Bedimo R . Non-AIDS-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep. 2013; 10(3):207-16. DOI: 10.1007/s11904-013-0166-8. View

12.

Stier E, Engels E, Horner M, Robinson W, Qiao B, Hayes J . Cervical cancer incidence stratified by age in women with HIV compared with the general population in the United States, 2002-2016. AIDS. 2021; 35(11):1851-1856. PMC: 8373779. DOI: 10.1097/QAD.0000000000002962. View

13.

Curtin S, Tejada-Vera B, Bastian B . Deaths: Leading Causes for 2020. Natl Vital Stat Rep. 2023; 72(13):1-115. View

14.

Bernstein W, Little R, Wilson W, Yarchoan R . Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol. 2006; 84(1):3-11. DOI: 10.1532/IJH97.06088. View

15.

Rahangdale L, Sarnquist C, Yavari A, Blumenthal P, Israelski D . Frequency of cervical cancer and breast cancer screening in HIV-infected women in a county-based HIV clinic in the Western United States. J Womens Health (Larchmt). 2010; 19(4):709-12. PMC: 2867552. DOI: 10.1089/jwh.2009.1412. View

16.

Hernandez-Ramirez R, Shiels M, Dubrow R, Engels E . Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017; 4(11):e495-e504. PMC: 5669995. DOI: 10.1016/S2352-3018(17)30125-X. View

17.

Castle P, Einstein M, Sahasrabuddhe V . Cervical cancer prevention and control in women living with human immunodeficiency virus. CA Cancer J Clin. 2021; 71(6):505-526. PMC: 10054840. DOI: 10.3322/caac.21696. View

18.

Curry S, Krist A, Owens D, Barry M, Caughey A, Davidson K . Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 320(7):674-686. DOI: 10.1001/jama.2018.10897. View